• Je něco špatně v tomto záznamu ?

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

S. Oliva, DHO. Bruinink, L. Rihova, M. D'Agostino, L. Pantani, A. Capra, B. van der Holt, R. Troia, MT. Petrucci, T. Villanova, P. Vsianska, R. Jugooa, C. Brandt-Hagens, M. Gilestro, M. Offidani, R. Ribolla, M. Galli, R. Hajek, F. Gay, M. Cavo,...

. 2021 ; 11 (6) : 106. [pub] 20210603

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012409

Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) is the most effective tool to define a deep response in multiple myeloma (MM). We conducted an MRD correlative study of the EMN02/HO95 MM phase III trial in newly diagnosed MM patients achieving a suspected complete response before maintenance and every 6 months during maintenance. Patients received high-dose melphalan (HDM) versus bortezomib-melphalan-prednisone (VMP) intensification, followed by bortezomib-lenalidomide-dexamethasone (VRd) versus no consolidation, and lenalidomide maintenance. Bone marrow (BM) samples were processed in three European laboratories, applying EuroFlow-based MFC protocols (eight colors, two tubes) with 10-4-10-5 sensitivity. At enrollment in the MRD correlative study, 76% (244/321) of patients were MRD-negative. In the intention-to-treat analysis, after a median follow-up of 75 months, 5-year progression-free survival was 66% in MRD-negative versus 31% in MRD-positive patients (HR 0.39; p < 0.001), 5-year overall survival was 86% versus 69%, respectively (HR 0.41; p < 0.001). MRD negativity was associated with reduced risk of progression or death in all subgroups, including ISS-III (HR 0.37) and high-risk fluorescence in situ hybridization (FISH) patients (HR 0.38;). In the 1-year maintenance MRD population, 42% of MRD-positive patients at pre-maintenance became MRD-negative after lenalidomide exposure. In conclusion, MRD by MFC is a strong prognostic factor. Lenalidomide maintenance further improved MRD-negativity rate.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012409
003      
CZ-PrNML
005      
20220506131305.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41408-021-00498-0 $2 doi
035    __
$a (PubMed)34083504
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Oliva, Stefania $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy. stefania.olivamolinet@gmail.com $1 https://orcid.org/000000023084180X
245    10
$a Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial / $c S. Oliva, DHO. Bruinink, L. Rihova, M. D'Agostino, L. Pantani, A. Capra, B. van der Holt, R. Troia, MT. Petrucci, T. Villanova, P. Vsianska, R. Jugooa, C. Brandt-Hagens, M. Gilestro, M. Offidani, R. Ribolla, M. Galli, R. Hajek, F. Gay, M. Cavo, P. Omedé, VHJ. van der Velden, M. Boccadoro, P. Sonneveld
520    9_
$a Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) is the most effective tool to define a deep response in multiple myeloma (MM). We conducted an MRD correlative study of the EMN02/HO95 MM phase III trial in newly diagnosed MM patients achieving a suspected complete response before maintenance and every 6 months during maintenance. Patients received high-dose melphalan (HDM) versus bortezomib-melphalan-prednisone (VMP) intensification, followed by bortezomib-lenalidomide-dexamethasone (VRd) versus no consolidation, and lenalidomide maintenance. Bone marrow (BM) samples were processed in three European laboratories, applying EuroFlow-based MFC protocols (eight colors, two tubes) with 10-4-10-5 sensitivity. At enrollment in the MRD correlative study, 76% (244/321) of patients were MRD-negative. In the intention-to-treat analysis, after a median follow-up of 75 months, 5-year progression-free survival was 66% in MRD-negative versus 31% in MRD-positive patients (HR 0.39; p < 0.001), 5-year overall survival was 86% versus 69%, respectively (HR 0.41; p < 0.001). MRD negativity was associated with reduced risk of progression or death in all subgroups, including ISS-III (HR 0.37) and high-risk fluorescence in situ hybridization (FISH) patients (HR 0.38;). In the 1-year maintenance MRD population, 42% of MRD-positive patients at pre-maintenance became MRD-negative after lenalidomide exposure. In conclusion, MRD by MFC is a strong prognostic factor. Lenalidomide maintenance further improved MRD-negativity rate.
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x aplikace a dávkování $7 D000971
650    _2
$a autologní štěp $7 D064592
650    _2
$a buňky kostní dřeně $x metabolismus $7 D001854
650    _2
$a bortezomib $x aplikace a dávkování $7 D000069286
650    _2
$a dexamethason $x aplikace a dávkování $7 D003907
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    12
$a průtoková cytometrie $7 D005434
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a lenalidomid $x aplikace a dávkování $7 D000077269
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melfalan $x aplikace a dávkování $7 D008558
650    _2
$a lidé středního věku $7 D008875
650    12
$a mnohočetný myelom $x metabolismus $x mortalita $x terapie $7 D009101
650    _2
$a reziduální nádor $7 D018365
650    _2
$a míra přežití $7 D015996
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bruinink, Davine Hofste Op $u Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands $u Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands $1 https://orcid.org/000000021296120X
700    1_
$a Rihova, Lucie $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic
700    1_
$a D'Agostino, Mattia $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
700    1_
$a Pantani, Lucia $u Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, S Orsola Malpighi Hospital, Bologna, Italy
700    1_
$a Capra, Andrea $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
700    1_
$a van der Holt, Bronno $u HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
700    1_
$a Troia, Rossella $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
700    1_
$a Petrucci, Maria Teresa $u Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
700    1_
$a Villanova, Tania $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
700    1_
$a Vsianska, Pavla $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Jugooa, Romana $u Department of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
700    1_
$a Brandt-Hagens, Claudia $u Department of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
700    1_
$a Gilestro, Milena $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
700    1_
$a Offidani, Massimo $u Clinica di Ematologia, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi di Ancona, Ancona, Italy
700    1_
$a Ribolla, Rossella $u Division of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
700    1_
$a Galli, Monica $u Dipartimento di Oncologia ed Ematologia, ASST Papa Giovanni XXIII, Bergamo, Italy
700    1_
$a Hajek, Roman $u Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Gay, Francesca $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
700    1_
$a Cavo, Michele $u Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, S Orsola Malpighi Hospital, Bologna, Italy
700    1_
$a Omedé, Paola $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
700    1_
$a van der Velden, Vincent H J $u Department of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands $1 https://orcid.org/0000000194573763
700    1_
$a Boccadoro, Mario $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy $1 https://orcid.org/0000000181305209
700    1_
$a Sonneveld, Pieter $u Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
773    0_
$w MED00187996 $t Blood cancer journal $x 2044-5385 $g Roč. 11, č. 6 (2021), s. 106
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34083504 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131257 $b ABA008
999    __
$a ok $b bmc $g 1789836 $s 1163610
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 6 $d 106 $e 20210603 $i 2044-5385 $m Blood cancer journal $n Blood Cancer J $x MED00187996
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace